Olmesartan Medoxomil Is Associated with Decreased Plasma AGEs, Pentosidine, and N-(Epsilon)-Carboxymethyl-Lysine Levels in Hemodialysis Patients

REFERENCES

• Stenvinkel P, Heimburger O, Paultre F, . Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55:1899–1911.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42:864–881.
   PubMed Web of Science ®Google Scholar
• Honda H, Qureshi AR, Heimbürger O, . Serum albumin, c-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47:139–148.
   PubMed Web of Science ®Google Scholar
• Honda H, Ueda M, Kojima S, . Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. Clin J Am Soc Nephrol 2009; 4:142–151.
   PubMed Web of Science ®Google Scholar
• Honda H, Ueda M, Kojima S, . Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2010; 5:1021–1028.
   PubMed Web of Science ®Google Scholar
• Meerwaldt R, Hartog JW, Graaff R, . Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3687–3693.
   PubMedGoogle Scholar
• Suliman ME, Heimbürger O, Bárány P, . Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14:1614–1622.
   PubMed Web of Science ®Google Scholar
• Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62:301–310.
   PubMed Web of Science ®Google Scholar
• Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006; 70:2109–2115.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Honda H, Niikura K, Akizawa T. Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis. Clin Exp Hypertens (in press).
   Google Scholar
• de Cavanagh EM, Ferder L, Carrasquedo F, . Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients. Am J Kidney Dis 1999; 34:445–455.
   PubMed Web of Science ®Google Scholar
• Chabrashvili T, Kitiyakara C, Blau J, . Effects of Ang II type 1 and 2 receptors on oxidative stress, renal NAPH oxidase, and sod expression. Am J Physiol Regul Integr Comp Physiol 2003; 285:R117–R124.
   PubMed Web of Science ®Google Scholar
• Miyata T, van Ypersele de Strihou C, Ueda Y, . Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13:2478–2487.
   PubMed Web of Science ®Google Scholar
• Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group. Serum levels of the advanced glycation end products N-epsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 2008; 108:c291–c297.
   PubMed Web of Science ®Google Scholar
• Alberti A, Bolognini L, Macciantelli D, Carratelli M. The radical cation of N,N-diethyl-para-phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed 2000; 26:253–256.
   Web of Science ®Google Scholar
• Suzuki H, Honda H, Kato N, . Assessment of inflow of endotoxin and its fragments in patients on maintenance hemodialysis. Blood Purif 2011; 31:268–275.
   PubMed Web of Science ®Google Scholar
• Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a Nephrologist’s perspective. Am J Kidney Dis 2000; 35:365–380.
   PubMed Web of Science ®Google Scholar
• Busch M, Franke S, Müller A, . Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66:338–347.
   PubMed Web of Science ®Google Scholar
• Suliman ME, Stenvinkel P, Jogestrand T, . Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006; 66:418–425.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yu Z, Jia H, . Association of serum pentosidine with arterial stiffness in hemodialysis patients. Artif Organs 2010; 34:193–199.
   PubMed Web of Science ®Google Scholar
• Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006; 70: 218–224.
   PubMed Web of Science ®Google Scholar
• Wagner Z, Molnár M, Molnár GA, . Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 2006; 47:294–300.
   PubMed Web of Science ®Google Scholar
• Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, . New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 1996; 11:41–47.
   PubMed Web of Science ®Google Scholar
• Del Vecchio L, Locatelli F, Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis—clinical effects, potential treatment, and prevention. Semin Dial 2011; 24:56–64.
   PubMed Web of Science ®Google Scholar
• Izuhara Y, Nangaku M, Inagi R, . Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16:3631–3641.
   PubMed Web of Science ®Google Scholar
• Fliser D, Wagner KK, Loos A, . Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16:1135–1140.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Hashimoto T, Kihara M, . Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. Nephron Exp Nephrol 2009; 111:e20–e30.
   PubMed Web of Science ®Google Scholar
• Shimada H, Kitamura K, Anraku M, . Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients. Hypertens Res 2005; 28:987–994.
   PubMed Web of Science ®Google Scholar
• Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7:140–145.
   PubMed Web of Science ®Google Scholar
• Nakano A, Hattori Y, Aoki C, Jojima T, Kasai K. Telmisartan inhibits cytokine-induced nuclear factor-kappa B activation independently of the peroxisome proliferator-activated receptor-gamma. Hypertens Res 2009; 32:765–769.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Noda Y, Yasuoka Y, . Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res 2008; 31:921–929.
   PubMed Web of Science ®Google Scholar
• Ohno K, Amano Y, Kakuta H, . Unique “delta lock” structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor. Biochem Biophys Res Commun 2011; 404:434–437.
   PubMed Web of Science ®Google Scholar
• Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46:585–593.
   PubMed Web of Science ®Google Scholar
• Nienhuis HL, Westra J, Smit AJ, . AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity 2009; 42:302–304.
   PubMed Web of Science ®Google Scholar
• Farmer DG, Kennedy S. RAGE, vascular tone and vascular disease. Pharmacol Ther 2009; 124:185–194.
   PubMed Web of Science ®Google Scholar